PULMATRIX, INC. Proceeds from Issuance of Warrants
PULMATRIX, INC. (PULM) reported Proceeds from Issuance of Warrants of $204.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-30.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfWarrants · last filed 2023-03-30
- PULMATRIX, INC. proceeds from issuance of warrants for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- PULMATRIX, INC. proceeds from issuance of warrants for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- PULMATRIX, INC. proceeds from issuance of warrants for the quarter ending 2021-06-30 was $0.00, a 100.00% decline year-over-year.
- PULMATRIX, INC. proceeds from issuance of warrants for the quarter ending 2021-03-31 was $204.00K, a 14.64% decline year-over-year.
- PULMATRIX, INC. proceeds from issuance of warrants for fiscal 2021 was $204.00K, a 98.50% decline from fiscal 2020.
- PULMATRIX, INC. proceeds from issuance of warrants for fiscal 2020 was $13.64M, a 8426.88% increase from fiscal 2019.
- PULMATRIX, INC. proceeds from issuance of warrants for fiscal 2019 was $160.00K.
| Period end | Proceeds from Issuance of Warrants 0 month | Proceeds from Issuance of Warrants 1 month | Proceeds from Issuance of Warrants 3 month | Proceeds from Issuance of Warrants 6 month | Proceeds from Issuance of Warrants 9 month | Proceeds from Issuance of Warrants 12 month |
|---|---|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $0.00 derived: sum of 2 quarters · filed 2023-03-30 | $0.00 derived: sum of 3 quarters · filed 2023-03-30 | $204.00K 10-K · filed 2023-03-30 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | $204.00K 10-Q · filed 2021-11-10 | $2.50M derived: sum of 4 quarters · filed 2022-03-29 | ||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $204.00K 10-Q · filed 2021-08-10 | $2.50M derived: sum of 3 quarters · filed 2022-03-29 | $13.07M derived: sum of 4 quarters · filed 2022-03-29 | ||
| 2021-03-31 | $204.00K 10-Q · filed 2021-05-11 | $2.50M derived: sum of 2 quarters · filed 2022-03-29 | $13.07M derived: sum of 3 quarters · filed 2022-03-29 | $13.61M derived: sum of 4 quarters · filed 2022-03-29 | ||
| 2020-12-31 | $2.29M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $12.87M derived: sum of 2 quarters · filed 2022-03-29 | $13.40M derived: sum of 3 quarters · filed 2022-03-29 | $13.64M 10-K · filed 2022-03-29 | ||
| 2020-09-30 | $10.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $11.11M derived: sum of 2 quarters · filed 2021-11-10 | $11.35M 10-Q · filed 2021-11-10 | $11.35M derived: sum of 4 quarters · filed 2021-11-10 | ||
| 2020-06-30 | $536.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $775.00K 10-Q · filed 2021-08-10 | $778.00K derived: sum of 3 quarters · filed 2021-08-10 | $782.00K derived: sum of 4 quarters · filed 2021-08-10 | ||
| 2020-04-20 | $1.14M 10-K · filed 2022-03-29 | |||||
| 2020-03-31 | $239.00K 10-Q · filed 2021-05-11 | $242.00K derived: sum of 2 quarters · filed 2021-05-11 | $246.00K derived: sum of 3 quarters · filed 2021-05-11 | $329.00K derived: sum of 4 quarters · filed 2021-05-11 | ||
| 2019-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | $7.00K derived: sum of 2 quarters · filed 2021-03-23 | $90.00K derived: sum of 3 quarters · filed 2021-03-23 | $160.00K 10-K · filed 2021-03-23 | ||
| 2019-09-30 | $4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-01 | $87.00K derived: sum of 2 quarters · filed 2019-11-01 | $157.00K 10-Q · filed 2019-11-01 | |||
| 2019-06-30 | $83.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $153.00K 10-Q · filed 2019-08-05 | ||||
| 2019-03-31 | $70.00K 10-Q · filed 2019-05-15 | |||||
| 2018-11-29 | $2.16M 10-K · filed 2020-03-26 | |||||
| 2018-09-30 | $78.00K 10-Q · filed 2019-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |